{
    "clinical_study": {
        "@rank": "67365", 
        "arm_group": [
            {
                "arm_group_label": "Arm I", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive oral letrozole once daily."
            }, 
            {
                "arm_group_label": "Arm II", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive oral placebo once daily."
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using\n      letrozole may fight breast cancer by reducing the production of estrogen.\n\n      PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in\n      treating women with breast cancer who have received tamoxifen for at least 5 years."
        }, 
        "brief_title": "Letrozole After Tamoxifen in Treating Women With Breast Cancer", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      Primary\n\n        -  Compare the disease-free survival and overall survival of postmenopausal women with\n           primary breast cancer who have completed at least five years of adjuvant aromatase\n           inhibitor as initial therapy or after tamoxifen treated with letrozole or placebo.\n\n      Secondary\n\n        -  Compare the incidence of contralateral breast cancer in patients treated with these\n           regimens.\n\n        -  Evaluate the long-term clinical and laboratory safety of letrozole, in terms of lipid\n           profile, cardiovascular morbidity and mortality, incidence of bone fractures, change in\n           bone density, and common toxic effects, in this patient population.\n\n        -  Compare the quality of life of patients treated with these regimens. Re-randomization\n\n      Primary\n\n        -  Compare disease-free survival of patients who, after receiving at least 4.5 years of\n           letrozole, are re-randomized to receive an additional 5 years of letrozole vs placebo.\n\n      Secondary\n\n        -  Determine whether common genetic polymorphisms for genes encoding proteins involved in\n           pharmacokinetic and/or pharmacodynamic pathways for letrozole contribute to individual\n           variation in toxicity and efficacy of letrozole therapy.\n\n      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients\n      are stratified according to receptor status (positive vs unknown), lymph node status\n      (negative vs positive vs unknown), prior adjuvant chemotherapy (yes vs no), interval between\n      last dose of aromatase inhibitor therapy and randomization (< 6 months vs 6 months-2 years),\n      and duration of prior tamoxifen use (0 years vs < 2 years vs 2-4.5 years vs > 4.5 years).\n      Patients are randomized to 1 of 2 treatment arms.\n\n        -  Arm I: Patients receive oral letrozole once daily.\n\n        -  Arm II: Patients receive oral placebo once daily. In both arms, treatment continues for\n           5 years in the absence of disease progression or unacceptable toxicity. Patients in arm\n           II may then be offered oral letrozole once daily for up to 5 years.\n\n      Quality of life is assessed at baseline, at 6 months, and then annually for 4.5 years.\n\n        -  Double-blind, re-randomization:\n\n      Patients who complete \u2265 4.5 years of letrozole (arm I) and who did not experience recurrent\n      disease or new primary breast cancer, including ductal carcinoma in situ, may participate in\n      the double-blind, placebo-controlled, re-randomization portion of the study. Patients are\n      stratified according to lymph node status at enrollment (negative vs positive vs unknown),\n      prior adjuvant chemotherapy (yes vs no), and interval between last dose of letrozole and\n      re-randomization (<6 months vs 6 months to 2 years). Common genetic single nucleotide\n      polymorphisms for genes encoding proteins involved in pharmacokinetic and/or pharmacodynamic\n      pathways for letrozole are analyzed in order to determine if these single nucleotide\n      polymorphisms contribute to individual variation in toxicity and efficacy of letrozole\n      therapy.\n\n      Quality of life is assessed as during the first randomization.\n\n      Patients are followed annually.\n\n      PROJECTED ACCRUAL: A total of 4,700 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed primary invasive breast carcinoma resected\n             at time of original diagnosis\n\n               -  No ductal carcinoma in situ\n\n          -  Axillary lymph node negative, positive, or unknown\n\n          -  No evidence of metastases\n\n          -  No localized or distant breast cancer recurrence\n\n          -  Not registered on protocol NCCTG-893052, any other IBCSG protocol, or protocol\n             SWOG-S9623\n\n          -  Hormone receptor status:\n\n               -  Estrogen or progesterone receptor positive as defined by tumor receptor content\n                  at least 10 fmol/mg protein or receptor positive by ERICA or PgRICA\n\n               -  Unknown status allowed if effort to determine status has been made by\n                  immunocytochemistry\n\n          -  No contralateral breast cancer\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Postmenopausal\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Postmenopausal defined by one of the following:\n\n               -  Age 50 or over at start of adjuvant tamoxifen\n\n               -  Under age 50 and considered postmenopausal by treating physician at start of\n                  adjuvant tamoxifen\n\n               -  Under age 50 at start of adjuvant tamoxifen and had bilateral oophorectomy\n                  (surgical or radiation)\n\n               -  Under age 50 and premenopausal at start of adjuvant tamoxifen, but became\n                  amenorrheic during tamoxifen and remained amenorrheic for at least 1 year\n\n               -  Considered postmenopausal by physician with LH/FSH levels under the treatment\n                  center's postmenopausal limits\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 5 years\n\n        Hematopoietic:\n\n          -  WBC \u2265 3,000/mm^3 OR\n\n          -  Granulocyte count \u2265 1,500/mm^3\n\n          -  Platelet count \u2265 100,000/mm^3\n\n        Hepatic:\n\n          -  AST and/or ALT < 2 times upper limit of normal (ULN) (unless imaging examinations\n             have ruled out metastatic disease)\n\n          -  Alkaline phosphatase < 2 times ULN (unless imaging examinations have ruled out\n             metastatic disease)\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  No concurrent medical or psychiatric condition that would preclude study\n             participation\n\n          -  No other malignancy within the past 5 years except adequately treated superficial\n             squamous cell or basal cell skin cancer or carcinoma in situ of the cervix\n\n          -  Able to swallow study drug\n\n          -  Adequate oral intake\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  Prior adjuvant chemotherapy allowed\n\n          -  No concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Completed at least 4.5 but no more than 6 years of adjuvant tamoxifen after resection\n\n          -  Completed at least 4.5-6 years of adjuvant aromatase inhibitor as initial therapy or\n             after tamoxifen\n\n          -  No more than 3 months since prior adjuvant tamoxifen\n\n          -  No concurrent hormone replacement therapy (e.g., megestrol)\n\n          -  No concurrent selective estrogen-receptor modulators (e.g., raloxifene or idoxifene)\n\n          -  Concurrent intermittent vaginal estrogens (e.g., Estring) allowed if other local\n             measures for intractable vaginal atrophy are insufficient\n\n          -  No other concurrent aromatase inhibitors\n\n          -  No more than 2 years since prior aromatase inhibitor therapy (re-randomization)\n\n        Radiotherapy:\n\n          -  Prior radiotherapy allowed\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  At least 1 month since prior investigational drugs\n\n          -  Prior treatment on a clinical trial for breast cancer allowed if permission has been\n             obtained from the sponsors of the original study for their patient to participate on\n             MA.17/JMA.17/BIG-97-01\n\n          -  No prior placebo on core protocol\n\n          -  No concurrent anticancer therapy\n\n          -  Concurrent thyroid medication, calcium, vitamin D, and bisphosphonates allowed"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "5187", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003140", 
            "org_study_id": "MA17", 
            "secondary_id": [
                "U10CA025224", 
                "CAN-NCIC-MA17", 
                "CALGB-49805", 
                "E-JMA17", 
                "EORTC-10983", 
                "IBCSG-BIG97-01", 
                "NCCTG-JMA17", 
                "SWOG-JMA17", 
                "JRF-Vor-Int-10", 
                "NCCTG-CAN-MA17", 
                "SWOG-CAN-MA17", 
                "CDR0000065921"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I", 
                "description": "Given orally", 
                "intervention_name": "letrozole", 
                "intervention_type": "Drug", 
                "other_name": "Femara"
            }, 
            {
                "arm_group_label": "Arm II", 
                "description": "Given orally", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tamoxifen", 
                "Letrozole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage I breast cancer", 
            "stage II breast cancer", 
            "stage IIIA breast cancer"
        ], 
        "lastchanged_date": "September 20, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CAN-NCIC-MA17"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lethbridge", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T1J 1W5"
                    }, 
                    "name": "Lethbridge Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kelowna", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V1Y 5L3"
                    }, 
                    "name": "BCCA - Cancer Centre for the Southern Interior"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanaimo", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V9S 2B7"
                    }, 
                    "name": "NRGH - Nanaimo Cancer Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Penticton", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V2A 3G6"
                    }, 
                    "name": "Penticton Regional Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V3V 1Z2"
                    }, 
                    "name": "BCCA - Fraser Valley Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "BCCA - Vancouver Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V8R 6V5"
                    }, 
                    "name": "BCCA - Vancouver Island Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3E 0V9"
                    }, 
                    "name": "CancerCare Manitoba"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moncton", 
                        "country": "Canada", 
                        "state": "New Brunswick", 
                        "zip": "E1C 6Z8"
                    }, 
                    "name": "The Moncton Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moncton", 
                        "country": "Canada", 
                        "state": "New Brunswick", 
                        "zip": "E1C 8X3"
                    }, 
                    "name": "The Vitalite Health Network - Dr. Leon Richard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint John", 
                        "country": "Canada", 
                        "state": "New Brunswick", 
                        "zip": "E2L 4L2"
                    }, 
                    "name": "Atlantic Health Sciences Corporation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. John's", 
                        "country": "Canada", 
                        "state": "Newfoundland and Labrador", 
                        "zip": "AIB 3V6"
                    }, 
                    "name": "Dr. H. Bliss Murphy Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H 1V7"
                    }, 
                    "name": "QEII Health Sciences Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barrie", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L4M 6M2"
                    }, 
                    "name": "The Royal Victoria Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre at Hamilton Health Sciences"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K7L 5P9"
                    }, 
                    "name": "Cancer Centre of Southeastern Ontario at Kingston"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "London Regional Cancer Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Markham", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L6B 1A1"
                    }, 
                    "name": "Markham Stouffville Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mississauga", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L5M 2N1"
                    }, 
                    "name": "Credit Valley Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newmarket", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L3Y 2P9"
                    }, 
                    "name": "Stronach Regional Health Centre at Southlake"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oshawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L1G 2B9"
                    }, 
                    "name": "Lakeridge Health Oshawa"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "Ottawa Health Research Institute - General Division"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peterborough", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K9H 7B6"
                    }, 
                    "name": "Peterborough Regional Health Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sault Ste. Marie", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P6B 0A8"
                    }, 
                    "name": "Algoma District Cancer Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Catharines", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L2R 7C6"
                    }, 
                    "name": "Niagara Health System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P3E 5J1"
                    }, 
                    "name": "Regional Cancer Program of the Hopital Regional"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thunder Bay", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P7B 6V4"
                    }, 
                    "name": "Thunder Bay Regional Health Science Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4N 3M5"
                    }, 
                    "name": "Odette Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X5"
                    }, 
                    "name": "Mount Sinai Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5B 1W8"
                    }, 
                    "name": "St. Michael's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M2K 1E1"
                    }, 
                    "name": "North York General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9N 1N8"
                    }, 
                    "name": "Humber River Regional Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M6R 1B5"
                    }, 
                    "name": "St. Joseph's Health Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4C 3E7"
                    }, 
                    "name": "Toronto East General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M9C 1A5"
                    }, 
                    "name": "Trillium Health Centre - West Toronto"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Univ. Health Network-Princess Margaret Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2C4"
                    }, 
                    "name": "Univ. Health Network-The Toronto General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Windsor", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N8W 2X3"
                    }, 
                    "name": "Windsor Regional Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottetown", 
                        "country": "Canada", 
                        "state": "Prince Edward Island", 
                        "zip": "C1A 8T5"
                    }, 
                    "name": "PEI Cancer Treatment Centre,Queen Elizabeth Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gatineau", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J8P 7H2"
                    }, 
                    "name": "Centre de Sante et de services sociaux de Gatineau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Levis", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G6V 3Z1"
                    }, 
                    "name": "L'Hotel-Dieu de Levis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2W 1T8"
                    }, 
                    "name": "CHUM - Hotel Dieu du Montreal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3X 3J4"
                    }, 
                    "name": "CHUM - Pavillon Saint-Luc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "CHUM - Hopital Notre-Dame"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H4J 1C5"
                    }, 
                    "name": "Hopital du Sacre-Coeur de Montreal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T 2M4"
                    }, 
                    "name": "Hopital Maisonneuve-Rosemont"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2W 1S6"
                    }, 
                    "name": "McGill University - Dept. Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec City", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G1R 2J6"
                    }, 
                    "name": "CHUQ-Pavillon Hotel-Dieu de Quebec"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec City", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G1S 4L8"
                    }, 
                    "name": "CHA-Hopital Du St-Sacrement"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J1H 5N4"
                    }, 
                    "name": "Centre hospitalier universitaire de Sherbrooke"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Regina", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S4T 7T1"
                    }, 
                    "name": "Allan Blair Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saskatoon", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S7N 4H4"
                    }, 
                    "name": "Saskatoon Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1V 4G5"
                    }, 
                    "name": "University Institute of Cardiology and"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW3 6JJ"
                    }, 
                    "name": "The Royal Marsden NHS Foundation Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M23 9LT"
                    }, 
                    "name": "Wythenshawe Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M2O 4BX"
                    }, 
                    "name": "Christie's Hospital NHS Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "United Kingdom", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "The Royal Marsden NHS Foundation Trust - Sutton"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen", 
        "overall_official": [
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "Paul E. Goss, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Mayo Clinic", 
                "last_name": "James N. Ingle, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University Hospital Inselspital, Berne", 
                "last_name": "Monica Castiglione-Gertsch, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Fairfax Northern Virginia Hematology Oncology, PC - Fairfax", 
                "last_name": "Nicholas J. Robert, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "John Wayne Cancer Institute at Saint John's Health Center", 
                "last_name": "Silvana Martino, DO", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Vermont", 
                "last_name": "Hyman B. Muss, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Institut Jules Bordet", 
                "last_name": "Martine J. Piccart-Gebhart, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Disease-free survival", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "reference": [
            {
                "PMID": "16046117", 
                "citation": "Baum M. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now? Eur J Cancer. 2005 Aug;41(12):1667-77. Review."
            }, 
            {
                "PMID": "15284712", 
                "citation": "Baum M. Current Status of Aromatase Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial. Cancer Control. 2004 Jul-Aug;11(4):217-21."
            }, 
            {
                "PMID": "17354227", 
                "citation": "Booth CM, Pater JL, Goss PE. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen. Cancer. 2007 Mar 12;109(9):1927-1928 [Epub ahead of print]"
            }, 
            {
                "PMID": "16870082", 
                "citation": "Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review."
            }, 
            {
                "PMID": "16526826", 
                "citation": "Scott LJ, Keam SJ. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. Drugs. 2006;66(3):353-62. Review."
            }, 
            {
                "PMID": "16912269", 
                "citation": "Vakaet L. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2006 Aug 16;98(16):1162; author reply 1162-3. No abstract available."
            }, 
            {
                "PMID": "16595026", 
                "citation": "Wardley AM. Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clin Breast Cancer. 2006 Feb;6 Suppl 2:S45-50. Review."
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003140"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "citation": "Goss PE, Ingle JN, Martino S, et al.: Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. [Abstract] 32nd Annual San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, Texas. A-13, 2009."
            }, 
            {
                "PMID": "18332475", 
                "citation": "Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20;26(12):1948-55. Epub 2008 Mar 10."
            }, 
            {
                "PMID": "18332043", 
                "citation": "Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008 Mar 10; [Epub ahead of print]"
            }, 
            {
                "PMID": "18332474", 
                "citation": "Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. J Clin Oncol. 2008 Mar 10; [Epub ahead of print]"
            }, 
            {
                "citation": "Chapman JW, Meng D, Shepherd L, et al.: Competing causes of death in breast cancer extended adjuvant endocrine therapy: NCIC CTG MA.17. [Abstract] American Society of Clinical Oncology 2007 Breast Cancer Symposium, 7-8 September 2007, San Francisco, California A-56, 2007."
            }, 
            {
                "PMID": "17452676", 
                "citation": "Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007 Apr 23; [Epub ahead of print]"
            }, 
            {
                "citation": "Goss P: Breaking the 5-year barrier: results from the MA.17 extended adjuvant trial in women who have completed adjuvant tamoxifen treatment. [Abstract] European Journal of Cancer Supplements 4 (9): 10-5, 2006."
            }, 
            {
                "PMID": "16541302", 
                "citation": "Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat. 2006 Oct;99(3):295-300. Epub 2006 Mar 16."
            }, 
            {
                "citation": "Ingle J, Tu D, Shepherd L, et al.: NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. [Abstract] J Clin Oncol 24 (Suppl 18): A-549, 2006."
            }, 
            {
                "citation": "Moy B, Tu D, Shepherd LE, et al.: NCIC CTG MA.17: tolerability of letrozole among ethnic minority women. [Abstract] J Clin Oncol 24 (Suppl 18): A-6018, 305s, 2006."
            }, 
            {
                "citation": "Pater JL, Tu D, Ingle JN, et al.: An evaluation of the early termination (ET) of MA.17 extended adjuvant therapy trial. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-2081, S107-8, 2006."
            }, 
            {
                "PMID": "16822845", 
                "citation": "Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006 Aug 1;24(22):3629-35. Epub 2006 Jul 5."
            }, 
            {
                "citation": "Robert NJ, Goss PE, Ingle JN, et al.: Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. [Abstract] J Clin Oncol 24 (Suppl 18): A-550, 2006."
            }, 
            {
                "citation": "Abetz L, Barghout V, Thomas S, et al.: Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-2047, 2005."
            }, 
            {
                "PMID": "16145047", 
                "citation": "Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71."
            }, 
            {
                "citation": "Goss PE, Ingle JN, Palmer MJ, et al.: Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-16, 2005."
            }, 
            {
                "citation": "Goss PE, Ingle JN, Tu D: NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-2042, 2005."
            }, 
            {
                "citation": "Ingle JN, Goss PE, Tu D: Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-17, 2005."
            }, 
            {
                "citation": "Luk C, Goss P, Pritchard K, et al.: Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. [Abstract] J Clin Oncol 23 (Suppl 16): A-642, 39s, 2005."
            }, 
            {
                "citation": "Vachon CM, Ingle JN, Scott CG, et al.: Pilot study of changes in mammographic density in women treated with letrozole or placebo on NCIC CTG MA17. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-6005, 2005."
            }, 
            {
                "PMID": "16157934", 
                "citation": "Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005 Oct 1;23(28):6931-40. Epub 2005 Sep 12."
            }, 
            {
                "citation": "Goss PE, Ingle JN, Martino S, et al.: Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. [Abstract] J Clin Oncol 22 (Suppl 14): A-847, 88s, 2004."
            }, 
            {
                "citation": "Whelan T, Goss P, Ingle J, et al.: Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. [Abstract] J Clin Oncol 22 (Suppl 14): A-517, 7s, 2004."
            }, 
            {
                "PMID": "14551341", 
                "citation": "Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6;349(19):1793-802. Epub 2003 Oct 9."
            }
        ], 
        "source": "NCIC Clinical Trials Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "North Central Cancer Treatment Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "International Breast Cancer Study Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Eastern Cooperative Oncology Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Southwest Oncology Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cancer and Leukemia Group B", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "NCIC Clinical Trials Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1998", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Algoma District Cancer Program": "46.522 -84.346", 
        "Allan Blair Cancer Centre": "50.455 -104.607", 
        "Atlantic Health Sciences Corporation": "45.273 -66.063", 
        "BCCA - Cancer Centre for the Southern Interior": "49.888 -119.496", 
        "BCCA - Fraser Valley Cancer Centre": "49.106 -122.828", 
        "BCCA - Vancouver Cancer Centre": "49.261 -123.114", 
        "BCCA - Vancouver Island Cancer Centre": "48.429 -123.366", 
        "CHA-Hopital Du St-Sacrement": "46.803 -71.243", 
        "CHUM - Hopital Notre-Dame": "45.509 -73.554", 
        "CHUM - Hotel Dieu du Montreal": "45.509 -73.554", 
        "CHUM - Pavillon Saint-Luc": "45.509 -73.554", 
        "CHUQ-Pavillon Hotel-Dieu de Quebec": "46.803 -71.243", 
        "Cancer Centre of Southeastern Ontario at Kingston": "44.231 -76.486", 
        "CancerCare Manitoba": "49.9 -97.137", 
        "Centre de Sante et de services sociaux de Gatineau": "45.484 -75.646", 
        "Centre hospitalier universitaire de Sherbrooke": "45.4 -71.884", 
        "Christie's Hospital NHS Trust": "53.479 -2.248", 
        "Credit Valley Hospital": "43.589 -79.644", 
        "Dr. H. Bliss Murphy Cancer Centre": "47.561 -52.713", 
        "Hopital Maisonneuve-Rosemont": "45.509 -73.554", 
        "Hopital du Sacre-Coeur de Montreal": "45.509 -73.554", 
        "Humber River Regional Hospital": "43.653 -79.383", 
        "Juravinski Cancer Centre at Hamilton Health Sciences": "43.244 -79.889", 
        "L'Hotel-Dieu de Levis": "46.803 -71.176", 
        "Lakeridge Health Oshawa": "43.89 -78.86", 
        "Lethbridge Cancer Centre": "49.693 -112.842", 
        "London Regional Cancer Program": "42.979 -81.246", 
        "Markham Stouffville Hospital": "43.883 -79.25", 
        "McGill University - Dept. Oncology": "45.509 -73.554", 
        "Mount Sinai Hospital": "43.653 -79.383", 
        "NRGH - Nanaimo Cancer Clinic": "49.166 -123.94", 
        "Niagara Health System": "43.159 -79.247", 
        "North York General Hospital": "43.653 -79.383", 
        "Odette Cancer Centre": "43.653 -79.383", 
        "Ottawa Health Research Institute - General Division": "45.422 -75.697", 
        "PEI Cancer Treatment Centre,Queen Elizabeth Hospital": "46.248 -63.12", 
        "Penticton Regional Hospital": "49.499 -119.594", 
        "Peterborough Regional Health Centre": "44.306 -78.322", 
        "QEII Health Sciences Center": "44.649 -63.575", 
        "Regional Cancer Program of the Hopital Regional": "46.49 -81.01", 
        "Saskatoon Cancer Centre": "52.134 -106.648", 
        "St. Joseph's Health Centre": "43.653 -79.383", 
        "St. Michael's Hospital": "43.653 -79.383", 
        "Stronach Regional Health Centre at Southlake": "44.053 -79.459", 
        "The Moncton Hospital": "46.088 -64.778", 
        "The Royal Marsden NHS Foundation Trust": "51.508 -0.128", 
        "The Royal Marsden NHS Foundation Trust - Sutton": "51.262 -0.467", 
        "The Royal Victoria Hospital": "44.378 -79.702", 
        "The Vitalite Health Network - Dr. Leon Richard": "46.088 -64.778", 
        "Thunder Bay Regional Health Science Centre": "48.416 -89.267", 
        "Toronto East General Hospital": "43.653 -79.383", 
        "Trillium Health Centre - West Toronto": "43.653 -79.383", 
        "Univ. Health Network-Princess Margaret Hospital": "43.653 -79.383", 
        "Univ. Health Network-The Toronto General Hospital": "43.653 -79.383", 
        "University Institute of Cardiology and": "52.94 -73.549", 
        "Windsor Regional Cancer Centre": "42.293 -82.993", 
        "Wythenshawe Hospital": "53.479 -2.248"
    }
}